Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Predictive Oncology ( (POAI) ).
Predictive Oncology Inc. faced potential delisting from The Nasdaq Capital Market due to non-compliance with the minimum stockholders’ equity and bid price requirements. After a hearing on July 17, 2025, Nasdaq granted the company an extension until December 8, 2025, to meet these requirements, though there is no assurance of compliance.
The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Underperform.
Predictive Oncology’s overall stock score is negatively impacted by severe financial instability, poor valuation metrics, and ongoing compliance issues with Nasdaq. The bearish technical indicators further suggest weak market sentiment, contributing to a low score.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Average Trading Volume: 174,951
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.14M
For an in-depth examination of POAI stock, go to TipRanks’ Overview page.